330 related articles for article (PubMed ID: 31619251)
1. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
[TBL] [Abstract][Full Text] [Related]
2. Hydroxyurea adherence and associated outcomes among Medicaid enrollees with sickle cell disease.
Candrilli SD; O'Brien SH; Ware RE; Nahata MC; Seiber EE; Balkrishnan R
Am J Hematol; 2011 Mar; 86(3):273-7. PubMed ID: 21328441
[TBL] [Abstract][Full Text] [Related]
3. The association between hydroxyurea adherence and opioid utilization among Texas Medicaid enrollees with sickle cell disease.
Kang HA; Barner JC
J Manag Care Spec Pharm; 2020 Nov; 26(11):1412-1422. PubMed ID: 33119448
[No Abstract] [Full Text] [Related]
4. The Economic Burden of End-Organ Damage Among Medicaid Patients with Sickle Cell Disease in the United States: A Population-Based Longitudinal Claims Study.
Campbell A; Cong Z; Agodoa I; Song X; Martinez DJ; Black D; Lew CR; Varker H; Chan C; Lanzkron S
J Manag Care Spec Pharm; 2020 Sep; 26(9):1121-1129. PubMed ID: 32597290
[TBL] [Abstract][Full Text] [Related]
5. Association of hydroxyurea adherence with transcranial Doppler screenings in children with sickle cell disease.
Knight LMJ; Tanabe P; Blewer AL; Goodrich J; King AA; Reuter-Rice K; Crego N
Pediatr Blood Cancer; 2024 Jul; 71(7):e31017. PubMed ID: 38706206
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.
Stallworth JR; Jerrell JM; Tripathi A
Am J Hematol; 2010 Oct; 85(10):795-7. PubMed ID: 20645429
[TBL] [Abstract][Full Text] [Related]
7. Impact of adherence to hydroxyurea on health outcomes among patients with sickle cell disease.
Kang HA; Barner JC; Lawson KA; Rascati K; Mignacca RC
Am J Hematol; 2023 Jan; 98(1):90-101. PubMed ID: 36251408
[TBL] [Abstract][Full Text] [Related]
8. Sickle-Cell Disease Co-Management, Health Care Utilization, and Hydroxyurea Use.
Crego N; Douglas C; Bonnabeau E; Earls M; Eason K; Merwin E; Rains G; Tanabe P; Shah N
J Am Board Fam Med; 2020; 33(1):91-105. PubMed ID: 31907250
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of treatment patterns, healthcare resource utilization and cost of illness for sickle cell disease in Ghana: a private medical insurance claims database study.
Marfo K; Dei-Adomakoh Y; Segbefia C; Dwomoh D; Edgal A; Ampah N; Ramachandrachar BC; Subramanyam K; Natarajan A; Egbujo O; Ataga KI
BMC Health Serv Res; 2023 Sep; 23(1):1018. PubMed ID: 37735428
[TBL] [Abstract][Full Text] [Related]
10. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea.
Lanzkron S; Haywood C; Segal JB; Dover GJ
Am J Hematol; 2006 Dec; 81(12):927-32. PubMed ID: 16924648
[TBL] [Abstract][Full Text] [Related]
11. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
[TBL] [Abstract][Full Text] [Related]
12. Age-related prescription medication utilization for the -management of sickle cell disease among Texas Medicaid patients.
Shukla N; Barner JC; Lawson KA; Rascati KL
J Opioid Manag; 2021; 17(4):301-310. PubMed ID: 34533824
[TBL] [Abstract][Full Text] [Related]
13. A Multidimensional Electronic Hydroxyurea Adherence Intervention for Children With Sickle Cell Disease: Single-Arm Before-After Study.
Creary S; Chisolm D; Stanek J; Hankins J; O'Brien SH
JMIR Mhealth Uhealth; 2019 Aug; 7(8):e13452. PubMed ID: 31397291
[TBL] [Abstract][Full Text] [Related]
14. Higher hydroxyurea adherence among young adults with sickle cell disease compared to children and adolescents.
Reddy PS; Cai SW; Barrera L; King K; Badawy SM
Ann Med; 2022 Dec; 54(1):683-693. PubMed ID: 35234095
[TBL] [Abstract][Full Text] [Related]
15. Cost analysis of acute care resource utilization among individuals with sickle cell disease in a middle-income country.
Lobo C; Moura P; Fidlarczyk D; Duran J; Barbosa R; Oliveira T; do Nascimento EM; Bhakta N; Hankins JS
BMC Health Serv Res; 2022 Jan; 22(1):42. PubMed ID: 34998394
[TBL] [Abstract][Full Text] [Related]
16. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia.
Vekeman F; Sasane M; Cheng WY; Ramanakumar AV; Fortier J; Qiu Y; Duh MS; Paley C; Adams-Graves P
J Med Econ; 2016; 19(3):292-303. PubMed ID: 26618853
[TBL] [Abstract][Full Text] [Related]
17. Hydroxyurea Initiation Among Children With Sickle Cell Anemia.
Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
Clin Pediatr (Phila); 2019 Nov; 58(13):1394-1400. PubMed ID: 31113236
[TBL] [Abstract][Full Text] [Related]
18. Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera.
Parasuraman SV; Shi N; Paranagama DC; Bonafede M
J Manag Care Spec Pharm; 2018 Jan; 24(1):47-55. PubMed ID: 29290171
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea Use for Sickle Cell Disease Among Medicaid-Enrolled Children.
Brousseau DC; Richardson T; Hall M; Ellison AM; Shah SS; Raphael JL; Bundy DG; Arnold S
Pediatrics; 2019 Jul; 144(1):. PubMed ID: 31227564
[TBL] [Abstract][Full Text] [Related]
20. Age-related treatment patterns in sickle cell disease patients and the associated sickle cell complications and healthcare costs.
Blinder MA; Vekeman F; Sasane M; Trahey A; Paley C; Duh MS
Pediatr Blood Cancer; 2013 May; 60(5):828-35. PubMed ID: 23335275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]